BioNTech challenges AstraZeneca with breast cancer precision drug trial

BioNTech (22UAy.DE), and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca (AZN.L), and Daiichi Sankyo (4568.T).